391 related articles for article (PubMed ID: 28132417)
1. Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics.
Smolle MA; Calin HN; Pichler M; Calin GA
FEBS J; 2017 Jul; 284(13):1952-1966. PubMed ID: 28132417
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory MicroRNAs in cancer: targeting immune checkpoints and the tumor microenvironment.
Omar HA; El-Serafi AT; Hersi F; Arafa EA; Zaher DM; Madkour M; Arab HH; Tolba MF
FEBS J; 2019 Sep; 286(18):3540-3557. PubMed ID: 31306553
[TBL] [Abstract][Full Text] [Related]
3. Regulation of cancer immune escape: The roles of miRNAs in immune checkpoint proteins.
Yang Q; Cao W; Wang Z; Zhang B; Liu J
Cancer Lett; 2018 Sep; 431():73-84. PubMed ID: 29800685
[TBL] [Abstract][Full Text] [Related]
4. Regulation of PD-1/PD-L1 Pathway in Cancer by Noncoding RNAs.
Ding L; Lu S; Li Y
Pathol Oncol Res; 2020 Apr; 26(2):651-663. PubMed ID: 31748880
[TBL] [Abstract][Full Text] [Related]
5. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
Wang Y; Wu L; Tian C; Zhang Y
Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
[TBL] [Abstract][Full Text] [Related]
6. Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.
Gorris MAJ; Halilovic A; Rabold K; van Duffelen A; Wickramasinghe IN; Verweij D; Wortel IMN; Textor JC; de Vries IJM; Figdor CG
J Immunol; 2018 Jan; 200(1):347-354. PubMed ID: 29141863
[TBL] [Abstract][Full Text] [Related]
7. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen J; Jiang CC; Jin L; Zhang XD
Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
[TBL] [Abstract][Full Text] [Related]
8. Noncoding RNAs in Cancer Immunology.
Li Q; Liu Q
Adv Exp Med Biol; 2016; 927():243-64. PubMed ID: 27376738
[TBL] [Abstract][Full Text] [Related]
9. The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint.
Wang Q; Lin W; Tang X; Li S; Guo L; Lin Y; Kwok HF
Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186904
[TBL] [Abstract][Full Text] [Related]
10. Firing Up Cold Tumors.
Cheng WC; Ho PC
Trends Cancer; 2019 Sep; 5(9):528-530. PubMed ID: 31474357
[TBL] [Abstract][Full Text] [Related]
11. MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers.
Peng L; Chen Z; Chen Y; Wang X; Tang N
Cancer Med; 2019 Dec; 8(17):7161-7173. PubMed ID: 31568700
[TBL] [Abstract][Full Text] [Related]
12. Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.
Mandai M; Hamanishi J; Abiko K; Matsumura N; Baba T; Konishi I
Int J Clin Oncol; 2016 Jun; 21(3):456-61. PubMed ID: 26968587
[TBL] [Abstract][Full Text] [Related]
13. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
Jiang X; Wang J; Deng X; Xiong F; Ge J; Xiang B; Wu X; Ma J; Zhou M; Li X; Li Y; Li G; Xiong W; Guo C; Zeng Z
Mol Cancer; 2019 Jan; 18(1):10. PubMed ID: 30646912
[TBL] [Abstract][Full Text] [Related]
14. Immune Modulatory microRNAs Involved in Tumor Attack and Tumor Immune Escape.
Eichmüller SB; Osen W; Mandelboim O; Seliger B
J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28383653
[TBL] [Abstract][Full Text] [Related]
15. Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells.
Ray A; Das DS; Song Y; Richardson P; Munshi NC; Chauhan D; Anderson KC
Leukemia; 2015 Jun; 29(6):1441-4. PubMed ID: 25634684
[No Abstract] [Full Text] [Related]
16. Noncoding RNAs as potential mediators of resistance to cancer immunotherapy.
Vishnubalaji R; Shaath H; Elango R; Alajez NM
Semin Cancer Biol; 2020 Oct; 65():65-79. PubMed ID: 31733291
[TBL] [Abstract][Full Text] [Related]
17. PD-1/PD-L1 Pathway in Breast Cancer.
Schütz F; Stefanovic S; Mayer L; von Au A; Domschke C; Sohn C
Oncol Res Treat; 2017; 40(5):294-297. PubMed ID: 28346916
[TBL] [Abstract][Full Text] [Related]
18. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
19. Molecular Characterization of Circulating Tumor Cells to Study Cancer Immunoevasion.
Nicolazzo C; Gradilone A; Carpino G; Gazzaniga P; Raimondi C
Methods Mol Biol; 2019; 1884():247-258. PubMed ID: 30465208
[TBL] [Abstract][Full Text] [Related]
20. Programmed death 1 (PD-1) and its ligand (PD-L1) as a new frontier in cancer Immunotherapy and challenges for the Pathologist: state of the art.
Callea M; Pedica F; Doglioni C
Pathologica; 2016 Jun; 108(2):48-58. PubMed ID: 28195250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
